Loy

In February 2025, LOY-002—a prescription pill from Loyal designed to extend healthy lifespan in senior dogs of nearly every size by targeting metabolic dysfunction—received its preliminary efficacy acceptance from the FDA, paving the way for it to potentially become the first-ever drug to give dogs more time with their families.

While LOY-002 targets senior dogs of every size, LOY-001 and LOY-003 are focused on extending the lifespan of large dogs, which can have much shorter lifespans than smaller dogs.

In fact, Tarantino has started the enrollment process for her own dog, an 11-year-old husky mix named Jose, in STAY, Loyal’s latest pivotal effectiveness trial for LOY-002’s Food and Drug Administration approval submission, which will run over the course of four years and aims to enroll up to 1,300 dogs.

Regardless, she is motivated to help LOY-002 reach approval.

Learner driver Jake Loy was jailed last year after he admitting killing his three friends by dangerous driving.